Diabetes Drugs and Cardioprotection: A Summary for Primary Care

These concise summaries highlight the latest findings on the cardioprotective effects of SGLT2 inhibitors and GLP-1 RA in patients with diabetes.

Recent study findings—many of which were presented at the recent American Diabetes Association (ADA) 81st Scientific Sessions—have demonstrated cardioprotective effects of sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). In the slides below, find concise summaries of the more significant developments in the use of diabetes drugs for ASCVD prevention.